Glucose Intolerance and the Amount of Visceral Adipose Tissue Contribute to an Increase in Circulating Triglyceride Concentrations in Caucasian Obese Females

Margot Berings1,3, Charline Wehlou1,*, An Verrijken2, Ellen Deschepper3, Ilse Mertens2, Jean-Marc Kaufman1, Luc F. Van Gaal3, D. Margriet Ouwens4, Johannes B. Ruige1*

1 Department of Endocrinology, Ghent University Hospital, Ghent, Belgium, 2 Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium, 3 Biostatistics Unit, Ghent University, Ghent, Belgium, 4 German Diabetes Center, Institute for Clinical Biochemistry and Pathobiochemistry, Düsseldorf, Germany

Abstract

Context: Lipotoxicity is a risk factor for developing obesity-related metabolic complications, including non-alcoholic fatty liver disease, type 2 diabetes (DM2), cardiovascular disease and stroke. Yet, the mechanisms underlying the development of lipotoxicity itself remain poorly understood. Here, we investigated whether glucose intolerance aggravates lipotoxicity by evaluating the association between triglyceride (TG) concentrations and glucose tolerance status in a cross-sectional study on obese Caucasian women at risk for DM2.

Methods: 913 obese females unknown to have diabetes were recruited (mean age: 41.2±SD 12.3; median BMI: 36.2, IQR 32.9–40.2). Visceral (VAT) and subcutaneous abdominal adipose tissue volumes were quantified with computed tomography. Glucose, insulin, and triglyceride concentrations were determined in fasting state and following a 75 gram oral glucose tolerance test.

Results: Based on fasting and 2 h post-load glucose levels, 27% of the women had impaired glucose tolerance (IGT), and 8% had newly diagnosed DM2. Fasting TG concentrations were similar between the IGT- and DM2-groups, and increased as compared to women with normal glucose tolerance (NGT). Even when adjusting for age, hip circumference and VAT, fasting TG concentrations remained elevated as compared to NGT. Mixed modelling analysis of post-load responses showed that TG concentrations declined more slowly in the DM2-group as compared to IGT and NGT. However, when adjusting for VAT the difference in decline between the glucose tolerance groups disappeared.

Conclusions: Glucose intolerance associates with elevated fasting TG concentrations in obese Caucasian women. We propose that glucose intolerance and increased VAT reduce lipid disposal mechanisms and may accelerate lipotoxicity.

Introduction

Lipotoxicity, or ectopic fat deposition of non-adipose tissue, may contribute to the development of metabolic complications of obesity, including type 2 diabetes (DM2), non-alcoholic fatty liver disease, cardiovascular dysfunction, and stroke [1]. Ectopic lipid deposition occurs when the lipid storage capacity of adipose tissue is insufficient [2]. Because the liver, pancreas, skeletal- and cardiac muscle, in which ectopic lipid deposition occurs, have a limited capacity for storing lipids, cellular dysfunction and death may occur in case of lipid overload [3,4].

Insight into mechanisms underlying the development of lipotoxicity are rapidly evolving, but still incompletely understood [5,6]. Although it seems reasonable to expect a systemic serum component, multiple studies indicate that circulating levels of non-esterified fatty acids (NEFA) are not directly related to the severity of obesity and its complications [5]. Rather, serum triglyceride (TG) concentrations might be critical for obesity-related metabolic risk assessment [7]. For example, fasting TG concentrations are importantly associated with body shape. Subjects with a large waist circumference, which is associated with increased risk for cardiovascular disease [8], have elevated TG concentrations, whereas subjects with a large hip circumference, which is associated with reduced risk [9,10], have reduced TG concentrations [7]. Accordingly, prospective studies in healthy young men could ascribe a substantial proportion of risk for both DM2 and cardiovascular disease to an increase in TG concentrations during a five year follow-up [11,12].

Since glucose intolerance is importantly associated with an elevated risk for DM2 and cardiovascular disease [13], we
investigated whether the presence of glucose intolerance may accelerate lipotoxicity in a cross-sectional study of a population at increased risk for developing DM2, i.e. obese women. We evaluated the association between glucose intolerance and fasting TG concentrations, as well as with the course of alterations in TG concentrations after an OGTT.

Methods

Setting and Participants

913 obese Caucasian females not known to have DM2 were recruited from the outpatient clinic of the Department of Diabetology, Metabolism, and Clinical Nutrition of the University Hospital, Antwerp, Belgium. Patients consulted for problems with their weight. Male patients were excluded as gender and/or sex steroids affect TG [14]. Participants who were 18 years or older, were included. Patients with very high fasting triglycerides (=7.7 mmol/L, Third Report of the National Cholesterol Education Program [15], suspected thyroid disease (thyroid-stimulating hormone <0,1 µU/ml and free T4 >18,8 pmol/L; or thyroid-stimulating hormone >4 µU/ml and free T4 <9,8 pmol/L), manifestly elevated liver tests (more than 5 fold the normal upper limits: aspartate transaminase >200 U/L, alanine transaminase >280 U/L, alkaline phosphatase >485 U/ L, gamma-glutamyl transferase >145 U/L) and elevated high-sensitivity C-reactive protein levels (=3.0 mg/dL may suggest the presence of a major infection) were excluded. In addition, patients using glucose or lipid-lowering medications and patients who had undergone bariatric surgery were excluded. The study was approved by the ethical committee of the Antwerp University Hospital, and the study was performed according to the standards on human experimentation in accordance with the Helsinki Declaration of 1975 as revised in 1983 with written informed consent of the participants.

Anthropometry and Imaging

All examinations were done in the morning between 8–10 h a.m. after an overnight fast. Length, body weight and hip circumference at the levels of the trochanter major were determined in a standard medical examination. Computed tomography at the L4–L5 level was carried out to measure the cross-sectional areas of visceral abdominal adipose tissue (VAT) and subcutaneous abdominal adipose tissue (SAT) according to the technique described by Van der Kooy and Seidell et al. [16].

Laboratory Analyses

Venous blood samples were collected in the fasting state and during the course of a glucose tolerance test at 30, 60, 90, 120, 150 and 180 minutes after the ingestion of 75 gram glucose. Plasma glucose was measured with the glucose oxidase method (on Vitros 750 XRC; Ortho Clinical Diagnostics Inc, Rochester, NY). Triglyceride levels were measured on Vitros 750XRC (Ortho Clinical Diagnostics, Johnson & Johnson, Raritan, NJ). Insulin was measured by a radioimmunoassay with the use of Pharmacia Insulin RIA (Pharmacy Diagnostics, Uppsala, Sweden). Insulin resistance was estimated using homeostasis model assessment (HOMA-IR) as described by Matthews et al [17]. Empty stomach was determined according to the criteria of the American Diabetes Association [18].

Statistical Analysis

Statistical calculations were carried out using IBM SPSS statistics version 19 (SPSS Inc an IBM company, Chicago, IL). Normal distribution of the data was verified with the Shapiro-Wilk test and graphical methods (box plots and Q-Q plots). Variables are presented as ± standard deviation or in case of non-Gaussian distribution as median (interquartile range). To show associations with fasting TG Pearson’s correlation coefficients were presented. If necessary in case of non-Gaussian distributed data, variables were normalized by transformation into their natural logarithm (Ln transformation). General linear modelling, which allows adjustment for confounding, was deployed to evaluate potential important determinants of fasting TG, including glucose tolerance status. Finally, mixed modelling, with random intercept for subjects to account for the dependency of the repeated measures, was used to analyze the glucose, insulin and TG response following glucose ingestion and to estimate fixed effects on the TG response of different variables of interest, such as VAT, and age. A P-value <0.05 was regarded as statistically significant.

Results

Ranking the participants based on their glucose tolerance status resulted in 593 normal glucose tolerant (NGT) -subjects, 244 impaired glucose tolerant (IGT) -subjects, and 72 subjects with newly diagnosed (DM2) (Table 1). Anthropometric and biochemical data of the 3 groups are presented in Table 1. Age of the NGT group was lower as compared to IGT and DM2. Body mass index (BMI) was lower in NGT versus IGT, but similar between IGT and DM2. VAT was lowest in NGT followed by IGT and DM2. SAT and hip circumference did not differ among the three groups. Fasting insulin levels and HOMA-IR were lowest in NGT followed by IGT and DM2. Fasting TG, as well as 2 h post-load insulin- and TG concentrations were similar between IGT and DM2 and elevated as compared to NGT.

To identify additional determinants, apart from the glucose tolerance status, of fasting TG concentrations, correlation coefficients were calculated. The strongest correlate appeared to be VAT, and then HOMA-IR (Table 2). Subsequently, multivariate linear regression analysis confirmed the independent association between fasting TG levels (dependent variable) and the glucose tolerance status, after adjustment for VAT, hip circumference and age (Table 3). Thus, independent of VAT, fasting TG levels were lower in females with NGT as compared to IGT or DM2.

To explore determinants of non-fasting TG concentrations, the TG response after an 75 gram OGTT was analyzed using mixed modelling. Figure 1 illustrates the alterations in glucose, insulin and triglyceride concentrations during the course of the OGTT in the three groups. As expected, the glucose curve differs according to glucose tolerance status. Also, the insulin curve differs according to glucose tolerance status. Specifically, the initial post-load increase in insulin concentrations is faster and the duration more limited in females with NGT, as compared to DM2, whereas the insulin curve of females with IGT showed an intermediate behaviour. Finally, the post-load TG concentrations showed on average a decline in the various groups which seemed to be reduced in females with DM2. Females with IGT showed a similar post-load TG curve as females with NGT, although their initial TG concentrations, as well as the post-load TG concentrations were elevated as compared to females with NGT.

Subsequently, additional determinants of TG concentrations after the OGTT were explored by mixed modelling analysis. This analysis identified VAT as the most important determinant of post-load TG concentrations. Accordingly, when distributing the participants into tertiles of VAT an almost equivalent distribution in post-load TG concentrations was observed among the three
groups (Figure 2). Furthermore, the initial difference between IGT and DM2 lost statistical significance after adjustment for VAT.

Thus, fasting TG concentrations were lower in obese females with NGT as compared to IGT or NDM. This effect is independent of VAT. In contrast, the alterations in post-load TG response among obese females with NGT, IGT or DM2 were found to be dependent on the amount of VAT.

**Discussion**

The present study displays an important link between fasting TG concentrations and glucose intolerance, as well as between the course of alterations in TG concentrations after an OGTT and the amount of VAT. These findings indicate that both glucose intolerance and increased amounts of VAT promote elevations in circulating TG concentrations, and thereby contribute to the development of lipotoxicity.

A limitation of the present study is that a general accepted systemic biomarker for lipotoxicity is not available. The use of NEFA has been heavily criticized: as adipose tissue mass expands, NEFA release per kilogram adipose tissue is downregulated, not increased [5]. NEFA concentrations might be modulated by altered function/expression of transporter proteins for fatty acids [19]. Based on former studies [7,11,12], we therefore used circulating TG levels as indicator for lipotoxicity. For non-fasting TG concentrations, the course of TG alterations after an OGTT was used instead of post-prandial TG levels after a standard mixed meal, as performing both tests was practically not feasible in more than 900 females. Another limitation is that results of the present study are not applicable to men or to females of African origin, as TG physiology is affected by sex steroids [14] and African descent

**Table 1.** Anthropometric and laboratory measurements of females subjects according to glucose tolerance status (n = 913).

|                  | NGT (n = 593) | IGT (n = 244) | DM2 (n = 72) | P         | P<sub>NGT-IGT</sub> | P<sub>NGT-DM2</sub> | P<sub>IGT-DM2</sub> |
|------------------|---------------|---------------|--------------|-----------|----------------------|----------------------|----------------------|
| Age (y)          | 38.74 (± 11.88) | 44.94 (± 12.06) | 48.14 (± 9.82) | 0.001     | < 0.001              | < 0.001              | < 0.001              |
| Weight (kg)      | 98.3 (87.6–109.3) | 100.9 (90.2–113.6) | 104.0 (90.1–114.4) | 0.006     | 0.017                | 0.077                | 0.883                |
| Height (m)       | 1.66 (± 0.07) | 1.65 (± 0.07) | 1.62 (± 0.06) | < 0.001   | 0.087                | < 0.001              | < 0.001              |
| BMI (kg/m<sup>2</sup>) | 35.6 (32.2–39.4) | 36.9 (33.5–42.1) | 39.0 (35.1–43.1) | < 0.001   | < 0.001              | < 0.001              | 0.155                |
| Hip circumference (cm) | 120.0 (± 9.9) | 119.4 (± 10.8) | 119.0 (± 12.4) | 0.595     | –                    | –                    | –                    |
| VAT (cm<sup>2</sup>) | 117.0 (90.3–162.0) | 156.7 (121.0–213.0) | 202.5 (149.5–283.8) | < 0.001   | < 0.001              | < 0.001              | 0.001                |
| SAT (cm<sup>2</sup>) | 572.1 (± 133.8) | 574.7 (± 123.5) | 587.8 (± 120.0) | 0.646     | –                    | –                    | –                    |
| Fasting plasma glucose (mmol/L) | 4.5 (4.2–4.7) | 4.7 (4.4–5.2) | 5.8 (5.1–6.7) | < 0.001   | < 0.001              | < 0.001              | < 0.001              |
| 2 hour plasma glucose (mmol/L) | 6.0 (5.2–6.7) | 8.6 (8.1–9.4) | 12.5 (11.5–14.3) | < 0.001   | < 0.001              | < 0.001              | < 0.001              |
| Fasting plasma insulin (pmol/L) | 93 (65–136) | 121 (72–158) | 158 (107–208) | < 0.001   | < 0.001              | < 0.001              | 0.004                |
| 2 hour plasma insulin (pmol/L) | 438 (265–782) | 861 (488–1356) | 753 (502–1435) | < 0.001   | < 0.001              | < 0.001              | 0.998                |
| HOMA-IR           | 2.5 (1.7–3.8) | 3.5 (2.2–5.1) | 5.8 (3.8–8.7) | < 0.001   | < 0.001              | < 0.001              | < 0.001              |
| Fasting plasma TG (mmol/L) | 1.3 (0.9–1.8) | 1.6 (1.2–2.1) | 1.6 (1.3–2.4) | < 0.001   | < 0.001              | < 0.001              | 0.973                |
| 2 hour plasma TG (mmol/L) | 1.1 (0.8–1.5) | 1.3 (1.0–1.8) | 1.3 (1.1–2.1) | < 0.001   | < 0.001              | < 0.001              | 0.590                |

VAT, visceral abdominal adipose tissue; SAT, subcutaneous abdominal adipose tissue; HOMA-IR, homeostasis model assessment (calculated insulin resistance); NGT, normal glucose tolerance; IGT, Impaired Glucose Tolerance; DM2, newly diagnosed type 2 diabetes.

Data are presented as mean (± SD) or median (25<sup>th</sup> percentile–75<sup>th</sup> percentile), in case of non-Gaussian distribution. Statistics according to ANOVA with Tukey correction for multiple comparisons. P, P value for overall difference between women with NGT, IGT and DM2; P<sub>NGT-IGT</sub>, P-value for difference between women with NGT and IGT; P<sub>NGT-DM2</sub>, P-value for difference between women with NGT and women with DM2; P<sub>IGT-DM2</sub>, P-value for differences between women with IGT and women with DM2.

doi:10.1371/journal.pone.0045145.t001

**Table 2.** Pearson correlations coefficients (r) between fasting serum triglycerides and potential determinants.

|                  | r   | P-value |
|------------------|-----|---------|
| Age              | 0.08| 0.022   |
| Weight           | 0.13| < 0.001 |
| Height           | –0.02| 0.644   |
| BMI              | 0.14| < 0.001 |
| Hip circumference| –0.09| 0.005  |
| VAT              | 0.28| < 0.001 |
| SAT              | 0.03| 0.478   |
| Fasting plasma glucose | 0.15| < 0.001 |
| 2 hour plasma glucose | 0.26| < 0.001 |
| Fasting plasma insulin | 0.21| < 0.001 |
| 2 hour plasma insulin | 0.20| < 0.001 |
| Calculated insulin resistance (HOMA-IR) | 0.23| < 0.001 |

*If appropriate, variables were transformed into their natural logarithm.

doi:10.1371/journal.pone.0045145.t002

**Table 3.** Results from general linear models with fasting serum triglycerides as dependent variable.

|                  | B    | SE    | P         |
|------------------|------|-------|-----------|
| Glucose tolerance status: |      |       | < 0.001   |
| IGT vs. NGT       | 0.125| 0.0346| < 0.001   |
| DM2 vs. NGT       | 0.079| 0.0564| 0.164     |
| VAT               | 0.316| 0.0377| < 0.001   |
| Hip circumference| –0.007| 0.0015| < 0.001   |
| Age               | –0.005| 0.0014| < 0.001   |

*If appropriate, variables were transformed into their natural logarithm.

doi:10.1371/journal.pone.0045145.t003
Although a substantial number of females (n = 336) used oral contraceptive pills or hormonal replacement therapy, we assume that the sample size of this epidemiological study evens potential individual effects on glucose- or lipid metabolism, as users are randomly distributed. Finally, there was no power calculation with a priori established primary end points, and the data are obtained in a cross-sectional study, because a prospective evaluation of patients with glucose intolerance or DM2 without treatment cannot be regarded as ethical. Despite these limitations, the present study provides arguments – for the first time based on a large population at risk – that a reduced capacity to dispose serum TG is the most likely explanation for the well known association between “the hypertriglyceridemic waist (estimate of amount of visceral adipose tissue)” and “high risk of CHD” in glucose intolerance and DM2 [8]. I.e. lipotoxicity is confirmed to be a main issue for CHD [21], and is related to glucose intolerance and VAT.

Changes in visceral fat of Japanese men have been associated with incident metabolic syndrome, such that investigators concluded that, for prevention, a lifestyle should be adopted that does not increase visceral fat [22]. The same study showed also a positive association between changes in visceral fat and changes in fasting TG concentrations, confirming that visceral adipose tissue and TG are strongly related. The waist circumference has not only been associated with metabolic syndrome, DM2 and cardiovascular disease [8], but also with liver fibrosis in children [23]. The present findings confirm the notion of the importance of body shape for lipotoxicity and obesity-related metabolic complications [2,7], and extent our knowledge by demonstrating that the amount of VAT is also a predominant regulator of non-fasting TG levels in obese females with or without a disturbed glucose metabolism. A dynamic study showed similar findings in detail in a limited number of obese males; they concluded that subjects with increased adiposity fails to appropriately upregulate meal fat-storage. This sign of maladaptation was thereafter suggested as the potential pathophysiologic basis of ectopic fat deposition in obesity [24].

Collectively, the results of the present study provide a meaningful direction for future research into obesity-related metabolic complications. I.e. new studies should aim to reveal the relationship between, on the one hand, the capacity to dispose serum lipids, and, on the other hand, glucose intolerance and the amount of visceral adipose tissue. Important questions that remain to be addressed include the mechanism underlying the positive association between TG concentrations and the amount of VAT, as well as the understanding of the association between elevated fasting glucose intolerance in obese subjects has been associated with metabolically “inflexible” high basal intramuscular triglyceride concentrations [25], confirming the relationship between glucose intolerance and lipotoxicity. The deregulation of intramyocellular fatty acid metabolism appears to be one of the initial features of insulin resistance of the skeletal muscle, closely linked to a reduced capacity to dispose lipids properly [2,26].

Collectively, the results of the present study provide a meaningful direction for future research into obesity-related metabolic complications. I.e. new studies should aim to reveal the relationship between, on the one hand, the capacity to dispose serum lipids, and, on the other hand, glucose intolerance and the amount of visceral adipose tissue. Important questions that remain to be addressed include the mechanism underlying the positive association between TG concentrations and the amount of VAT, as well as the understanding of the association between elevated fasting glucose intolerance in obese subjects has been associated with metabolically “inflexible” high basal intramuscular triglyceride concentrations [25], confirming the relationship between glucose intolerance and lipotoxicity. The deregulation of intramyocellular fatty acid metabolism appears to be one of the initial features of insulin resistance of the skeletal muscle, closely linked to a reduced capacity to dispose lipids properly [2,26].

Collectively, the results of the present study provide a meaningful direction for future research into obesity-related metabolic complications. I.e. new studies should aim to reveal the relationship between, on the one hand, the capacity to dispose serum lipids, and, on the other hand, glucose intolerance and the amount of visceral adipose tissue. Important questions that remain to be addressed include the mechanism underlying the positive association between TG concentrations and the amount of VAT, as well as the understanding of the association between elevated fasting glucose intolerance in obese subjects has been associated with metabolically “inflexible” high basal intramuscular triglyceride concentrations [25], confirming the relationship between glucose intolerance and lipotoxicity. The deregulation of intramyocellular fatty acid metabolism appears to be one of the initial features of insulin resistance of the skeletal muscle, closely linked to a reduced capacity to dispose lipids properly [2,26].
TG concentrations and visceral adipocyte size [6]? Finally, it remains to be established to what extent alterations in adipokine secretion from enlarged VAT contribute to the reduced capacity to dispose serum lipids [27]. In conclusion, fasting TG concentrations are associated with impaired glucose tolerance in obese Caucasian females, and the course of alterations in TG concentrations after an OGTT is determined by the amount of VAT. The findings suggest that glucose intolerance and the amount of VAT interfere with disposing of serum lipids.

Supporting Information

Information S1 Results of mixed modelling analysis: glucose response according to glucose tolerance (Tables S1); Insulin resistance: time for a reevaluation. Diabetes 60: 2441–2449.

References

1. Haffner SM, Lehto S, Ronnemaa T, Pyorälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339: 229–234.
2. Frayn KN (2002) Adipose tissue as a buffer for daily lipid flux. Diabetesologia 45: 1201–1210.
3. Lodhi IJ, Wei X, Semenovich CF (2011) Lipoperoxidase: de novo lipogenesis as a metabolic signal transmitter. Trends Endocrinol Metab 22: 1–83.
4. Van Gaal LF, Mertens I, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444: 873–880.
5. Karpe F, Dickmann JR, Frayn KN (2011) Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 60: 2441–2449.
6. De Naeyer H, Ouwens DM, Van Nieuwenhove Y, Pattyn P, ’t Hart LM, et al. (2011) Combined Gene- and Protein Expression of Hormone-Sensitive Lipase and Adipose Triacylglyceride Lipase, Mitochondrial Content and Adipocyte Size in Subcutaneous and Visceral Adipose Tissue of Morbidly Obese Men. Obes Facts 4: 407–416.
7. Ruige JB, Van Gaal L (2009) Low fasting triacylglycerides: Hallmark of the Healthy Large Hip? Obesity 17: 1621–1626.
8. St-Pierre J, Lemieux I, Perron P, Brison D, Santuré M, et al. (2007) Relation of the "hyperglycemicemic waist" phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus. Am J Cardiol 99: 369–373.
9. Manolopoulos KN, Karpe F, Frayn KN (2010) Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond) 34: 949–959.
10. Lisson I, Bjoelkelund C, Heitmann BL, Ouwens DM, ’t Hart LM, et al. (2011) Larger hip circumference independently predicts health and longevity in a Swedish female cohort. Obes Res 9: 644–646.
11. Tirosh A, Rudich A, Shochat T, Teles-Manova D, Israeli E, et al. (2007) Changes in triglyceride levels and risk for coronary heart disease in young men. Am J Intern Med 147: 377–383.
12. Tirosh A, Shai I, Bitzur R, Kochba I, Teles-Manova D, et al (2008) Changes in triglyceride levels over time and risk of type 2 diabetes in young men. Diabetes Care 31: 2032–2037.
13. DeFronzo RA, Abdul-Ghani M (2011) Combined Gene- and Protein Expression of Hormone-Sensitive Lipase and Adipose Triacylglyceride Lipase, Mitochondrial Content and Adipocyte Size in Subcutaneous and Visceral Adipose Tissue of Morbidly Obese Men. Obes Facts 4: 407–416.
14. Lapanae B, Ouwens M, ’t Hart LM, Wuyts B, Holst JJ, et al. (2010) Sex steroids affect triglyceride handling, glucose-dependent insulinstotropic polypeptide, and insulin sensitivity: a 1-week randomized clinical trial in healthy young men. Diabetes Care 33: 1831–1833.
15. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 106: 3143–3421.
16. Van der Kooy K, Seidell JC (1993) Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 17: 167–196.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.
18. Follow-up Report of the Diagnosis of Diabetes Mellitus 2005. The expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26: 3160–3167.
19. Holloway GP, Lushark JJ, Glatt JF, Spriet LL, Bonen A (2006) Contribution of FAT/CD36 to the regulation of skeletal muscle fatty acid oxidation: an overview. Acta Physiol (Oxf) 194: 293–309.
20. Yu SS, Castillo DC, Courville AB, Sumner AE (2012) The triglyceride paradox in people of African descent. Metab Syndr Relat Disord 10: 77–92.
21. Neir W, Shalata A, Marmor A, Assy N (2011) Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 56: 3439–3449.
22. Matushita Y, Nakagawa T, Yamamoto S, Takahashi Y, Yokoyama T, et al. (2012) Effect of longitudinal changes in visceral fat area and other anthropometric indices to the changes in metabolic risk factors in Japanese men: the Hitachi health study. Diabetes Care 35: 1139–1143.
23. Manco M, Bedogni G, Marcellini M, Devito R, Ciampalini P, et al. (2008) Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut 57: 1201–1207.
24. McQuaid SE, Hodson L, Neville MJ, Dennis AL, Cheeseman J, et al. (2011) Downregulation of adipose tissue fatty acid trafficking in obesity. A driver for ectopic fat deposition? Diabetes 60: 47–55.
25. Perretault L, Bergman RC, Huerdessode DM, Playdon MC, Eckel RH (2010) Inflowlarity in intramuscular triglyceride fractional synthesis distinguishes prediabetes from obesity in humans. Obesity (Silver Spring). 18: 1524–1531.
26. Petersen KE, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350: 664–671.
27. Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115: 1111–1119.